HE4 as a biomarker for ovarian and endometrial cancer management

Jinping Li, Sean Christopher Dowdy, Tracy Tipton, Karl Podratz, Wei Guo Lu, Xing Xie, Shi Wen Jiang

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Ovarian and endometrial cancer will be diagnosed in over 63,000 women in 2009, resulting in 22,000 deaths in the USA. Histologic screening, such as pap smears for detection of cervical cancer, is not feasible for these diseases given difficulty with access to the tissue. Thus, a serum-screening test using a biomarker or panel of biomarkers would be useful to aid in cancer diagnosis, detection of recurrence and as a means to monitor response to therapy. In this review, we focus on the human epididymis protein (HE)4 gene, which appears to have potential as a biomarker for both of these diseases. The structure and methods of detection of HE4 are discussed. Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date. Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk.

Original languageEnglish (US)
Pages (from-to)555-566
Number of pages12
JournalExpert Review of Molecular Diagnostics
Volume9
Issue number6
DOIs
StatePublished - Sep 2009

Fingerprint

Endometrial Neoplasms
Ovarian Neoplasms
Biomarkers
Papanicolaou Test
Epididymis
Uterine Cervical Neoplasms
Neoplasms
Antigens
Recurrence
Serum
Proteins
Therapeutics

Keywords

  • Cancer antigen 125
  • Cancer diagnosis and treatment
  • Endometrial cancer
  • Human epididymis protein 4
  • Ovarian cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

HE4 as a biomarker for ovarian and endometrial cancer management. / Li, Jinping; Dowdy, Sean Christopher; Tipton, Tracy; Podratz, Karl; Lu, Wei Guo; Xie, Xing; Jiang, Shi Wen.

In: Expert Review of Molecular Diagnostics, Vol. 9, No. 6, 09.2009, p. 555-566.

Research output: Contribution to journalArticle

Li, Jinping ; Dowdy, Sean Christopher ; Tipton, Tracy ; Podratz, Karl ; Lu, Wei Guo ; Xie, Xing ; Jiang, Shi Wen. / HE4 as a biomarker for ovarian and endometrial cancer management. In: Expert Review of Molecular Diagnostics. 2009 ; Vol. 9, No. 6. pp. 555-566.
@article{e56e9c0591b245e98c855679fff837c9,
title = "HE4 as a biomarker for ovarian and endometrial cancer management",
abstract = "Ovarian and endometrial cancer will be diagnosed in over 63,000 women in 2009, resulting in 22,000 deaths in the USA. Histologic screening, such as pap smears for detection of cervical cancer, is not feasible for these diseases given difficulty with access to the tissue. Thus, a serum-screening test using a biomarker or panel of biomarkers would be useful to aid in cancer diagnosis, detection of recurrence and as a means to monitor response to therapy. In this review, we focus on the human epididymis protein (HE)4 gene, which appears to have potential as a biomarker for both of these diseases. The structure and methods of detection of HE4 are discussed. Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date. Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk.",
keywords = "Cancer antigen 125, Cancer diagnosis and treatment, Endometrial cancer, Human epididymis protein 4, Ovarian cancer",
author = "Jinping Li and Dowdy, {Sean Christopher} and Tracy Tipton and Karl Podratz and Lu, {Wei Guo} and Xing Xie and Jiang, {Shi Wen}",
year = "2009",
month = "9",
doi = "10.1586/erm.09.39",
language = "English (US)",
volume = "9",
pages = "555--566",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - HE4 as a biomarker for ovarian and endometrial cancer management

AU - Li, Jinping

AU - Dowdy, Sean Christopher

AU - Tipton, Tracy

AU - Podratz, Karl

AU - Lu, Wei Guo

AU - Xie, Xing

AU - Jiang, Shi Wen

PY - 2009/9

Y1 - 2009/9

N2 - Ovarian and endometrial cancer will be diagnosed in over 63,000 women in 2009, resulting in 22,000 deaths in the USA. Histologic screening, such as pap smears for detection of cervical cancer, is not feasible for these diseases given difficulty with access to the tissue. Thus, a serum-screening test using a biomarker or panel of biomarkers would be useful to aid in cancer diagnosis, detection of recurrence and as a means to monitor response to therapy. In this review, we focus on the human epididymis protein (HE)4 gene, which appears to have potential as a biomarker for both of these diseases. The structure and methods of detection of HE4 are discussed. Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date. Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk.

AB - Ovarian and endometrial cancer will be diagnosed in over 63,000 women in 2009, resulting in 22,000 deaths in the USA. Histologic screening, such as pap smears for detection of cervical cancer, is not feasible for these diseases given difficulty with access to the tissue. Thus, a serum-screening test using a biomarker or panel of biomarkers would be useful to aid in cancer diagnosis, detection of recurrence and as a means to monitor response to therapy. In this review, we focus on the human epididymis protein (HE)4 gene, which appears to have potential as a biomarker for both of these diseases. The structure and methods of detection of HE4 are discussed. Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date. Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk.

KW - Cancer antigen 125

KW - Cancer diagnosis and treatment

KW - Endometrial cancer

KW - Human epididymis protein 4

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=69949188760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949188760&partnerID=8YFLogxK

U2 - 10.1586/erm.09.39

DO - 10.1586/erm.09.39

M3 - Article

C2 - 19732003

AN - SCOPUS:69949188760

VL - 9

SP - 555

EP - 566

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 6

ER -